Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

New Drugs 2014-2015 for Pharmacy Technicians


This CE activity was originally published in The Rx Consultant.  If you received credit for it previously, you cannot receive credit for it again.
 
2014 was an exciting year for new drug approvals and,according to Forbes, the best since the all-time record in 1996.The FDA approved 44 novel agents: 39 (excluding imaging agents) by the Center for Drug Evaluation and Research (CDER) and 5 (including only recombinant agents) by the Center for Biologics Evaluation and Research (CBER).Seventeen of the CDER approvals are considered first-in-class,and span 10 therapeutic areas led by infectious diseases, cancer, and rare diseases.Three more novel drugs were approved in the first 6 weeks of 2015;2 of the 3 are first-in-class. The increased rate of approvals may be related to the FDA’s effort to ensure that treatments for serious conditions are approved as soon as there is enough evidence that their benefits outweigh their risks. Four expedited programs were established: fast track designation, accelerated approval,priority review, and breakthrough therapy designation.Many of the recently approved drugs took advantage of these approaches.

Given the large number of approvals, The Rx Consultant will publish 2 New Drugs issues this year. The first issue provides detailed reviews of inhaled human insulin,2 weight loss products, 2 products for chronic hepatitis C virus infection, and a first-in-class orexin receptor antagonist for insomnia. Usual doses and selected drug interactions are summarized in Table 1.Eleven more new drugs that are likely to be encountered in everyday practice are described in Table 2.
 
Format
This CE activity is a monograph (PDF file).

Fee

$10.00

CE Hours

1.50

CE Units

0.150

Activity Type

  • Knowledge-based

Target Audience(s)

  • This accredited program is targeted to pharmacy technicians.

Accreditation(s)

This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.

CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours.  CE credit is automatically reported to CPE Monitor.
 
CE activities for Nurse Practitioners and Clinical Nurse Specialists: 
    This continuing education activity meets the requirements of:
        The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
        The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
 
    This is a pharmacotherapeutics/pharmacology CE activity.
  • The ANCC requires all advanced practice nursing certificants (CNSs and NPs) to complete 25 CE hours of pharmacotherapeutics as a portion of the required 75 continuing education hours.
  • Pharmacology CE is recommended by the AANPCP and will be required for Certificants renewing certification starting January 2017.  
  • Most State Boards of Nursing require a minimum number of pharmacy contact hours to renew an advanced practice license.
 
 
Accreditation Council for Pharmacy Education
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Requirements for CE Credit

To receive CE credit, the participant must read the monograph in its entirety, complete the online post-test and receive a score of 70% or greater, and complete the online evaluation.
 
Pharmacy Technicians -
 
Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits cannot be reported to CPE Monitor.
 
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation are successfully completed.

 

 

 

Objectives

  • For each of the drugs reviewed: List the generic name, brand name, FDA approved indications, and usual dose
  • Describe significant side effects and drug interactions.
  • For each drug listed in Table 2: List the generic name, brand name, and FDA approved indication(s)

Activity Number

0428-000-15-003-H01-T

Release Date: Mar 31, 2015
Credit Expiration Date: Mar 30, 2018

CE Hours

1.50

Fee

$10.00
 

The CE Activity developed by The Rx Consultant